11 news items
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79
RYTM
8 May 24
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $80 to $79.
B of A Securities Downgrades Rhythm Pharmaceuticals to Neutral, Lowers Price Target to $42
RYTM
8 May 24
B of A Securities analyst Tazeen Ahmad downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Buy to Neutral and lowers the price target from $49 to $42.
Needham Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $46
RYTM
7 May 24
Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $50 to $46.
Rhythm Pharmaceuticals Announces Publication Of Results From Phase 2 Study Of Setmelanotide For The Treatment Of Hypothalamic Obesity In The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
, Department of Pediatrics, University of Washington. "In this first study to investigate the use of setmelanotide as a targeted treatment
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
and Division of Endocrinology, Department of Pediatrics, University of Washington. "In this first study to investigate the use of setmelanotide as a targeted
7imtau5uk9w1gbuhjdlijeisx8
RYTM
26 Apr 24
0
In the assessment of 12-month price targets, analysts unveil insights for Rhythm Pharmaceuticals, presenting
cziyq831ncwwfobm1hsvo0sm0u mulmse
RYTM
26 Apr 24
Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $50 price target.
6qp550 c1g
RYTM
18 Apr 24
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price target from $53 to $52.
jsapzeza3meut7ztc80 o5jcmrfdaf
ATNM
AZN
BMY
18 Apr 24
(NYSE:ATNM), which recently saw its price target raised by Maxim from $20 to $30. The adjustment follows the company's strategic move
y15h56r30s0jp5s
RYTM
10 Apr 24
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $50.8, a high estimate of $52.00
vlftk7x9lgon17w3jcjyk75z6x48f
RYTM
10 Apr 24
Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $50 price target.
- Prev
- 1
- Next